| Name | Title | Contact Details |
|---|
OakStar Bank strives to prove each day that banking can and should be a joyful and fun experience. By creating a unique work culture that is rooted and cultivated throughout every aspect of the bank, OakStar team members love what they do, love the people they work with, and love serving the community. The banks commitment to their values and their culture has resulted in the creation of a uniquely new banking experience that is comfortable, warm, and completely relationship based… ultimately a place where customers look forward to going. OakStar Banks passion is to create a positive difference for its customers and leave a long-lasting legacy in the community.
Columbus Mckinnon is a New York-based company that manufactures and distributes material handling products including hoists and cranes for sectors such as food and utilities.
Growscape is a North American horticultural company formed from the merger of The HC Companies and Classic Home & Garden. It serves a wide range of markets, including growers, retailers, distributors, nurseries, greenhouses, and home gardeners. Growscape offers innovative and sustainable products such as growing containers, decorative planters, garden décor, and protective packaging. With dual headquarters in Twinsburg, Ohio, and Shelton, Connecticut, Growscape operates manufacturing and distribution facilities across the U.S., Canada, and China. The company employs between 501 and 1000 people and emphasizes eco-efficient manufacturing processes. Growscape is committed to sustainability, focusing on reducing carbon footprints and promoting circular solutions. Its product offerings include various types of growing containers made from sustainable materials, as well as decorative items crafted from diverse materials. Growscape also provides customer-driven services, including collaborative product ideation and expert logistics, to support its partners in the horticultural industry.
Elementary is a company specializing in advanced machine vision inspection, utilizing AI and automation to enhance manufacturing processes. Founded in mid-2017 by experienced professionals from various sectors, the company aims to develop a new generation of manufacturing products that rely on computer vision and AI. Their platform automates traceability scans and integrates AI, machine vision, and automation into production lines. This approach focuses on improving quality, traceability, and root cause analyses, making manufacturing processes more efficient. Elementary emphasizes a human-in-the-loop strategy, enhancing collaboration between humans and machines to optimize working conditions and outcomes. Based in Los Angeles, California, Elementarys team includes roboticists, computer scientists, designers, and engineers. The company has attracted significant funding, including a $30 million Series B round led by Tiger Global, to support its innovative solutions in manufacturing. Their technology is utilized by notable clients across various industries, including Toyota in the automotive sector.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.